Eli Lilly reports China’s NMPA approves Innovent’s Tyvyt for Hodgkin’s Lymphoma Innovent and Eli Lilly jointly announced that the co-developed Tyvyt has been granted approval for market authorization by the National Medical Products Administration of China, or “NMPA”, formerly the China Food and Drug Administration, for the treatment of patients with classical Hodgkin’s lymphoma that has relapsed or refractory after two or more lines of systemic chemotherapy. Dr. Wang Li, Senior Vice-President of Lilly China and Head of Lilly China Drug Development and Medical Affairs, said, “The efficacy and safety profile of Tyvyt is well proven in the ORIENT-1 trial. The drug provides a new immuno-oncology treatment option for patients with relapsed/refractory classical Hodgkin’s lymphoma. Lilly will continue to collaborate with outstanding local pharmaceutical companies to bring more innovative medicines to patients and help in demonstrating local R&D capabilities in global oncology community.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.